ArticleScientific reports2025
Identification of a novel unfolded protein response related signature for predicting the prognosis of acute myeloid leukemia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Machine learning-driven development of a novel unfolded protein response-related gene signature for predicting lung adenocarcinoma patient prognosis.BMC cancer · 2026Article
- Hepatic cellular stress response pathways exhibit species differences in basal and inducible activity.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The unfolded protein response (UPR) plays a pivotal role in the pathogenesis and progression of acute myeloid leukemia (AML). This study aims to investigate the prognostic value of UPR-related genes (URGs) and establish a UPR-related gene signature (URGsig) to enhance prognosis prediction and guide therapeutic decision-making in AML. Gene expression profiles of AML patients were obtained from the GDC and GEO databases. Cox regression and LASSO regression analyses were applied to identify key genes for the construction of URGsig. Comprehensive bioinformatics analyses were conducted to elucidate the biological and clinical implications of URGsig. A nomogram integrating URGs and clinical prognostic features was developed to predict survival probability for AML patients. Additionally, the differential expression of core genes within the URGsig was validated in clinical samples. Notably, two distinct UPR-related subtypes were identified, and they displayed significant heterogeneity in clinical outcomes and tumor microenvironment (TME). The URGsig, comprising six URGs, showed a strong correlation with survival outcomes and exhibited robust predictive capabilities. Importantly, patients categorized into the high-risk subgroup based on URGsig were predicted to show lower chemosensitivity but a better response to immunotherapy. The nomogram performed well in prognosis prediction, with an area under the curve (AUC) of 0.912 for 5-year overall survival. In summary, our findings highlight the URGsig as a promising prognostic biomarker and provide novel insights into the mechanism by which UPR influences the immune landscape of AML. This paradigm may lay a foundation for the development of personalized treatment strategies for AML patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.